Wyszukiwarka
Abstrakt
The receptor for advanced glycation end-products (RAGE) has been implicated in driving prostate cancer (PCa) growth, aggression, and metastasis through the fueling of chronic inflammation in the tumor microenvironment. This systematic review and meta-analysis summarizes and analyzes the current clinical and preclinical data to provide insight into the relationships among RAGE levels and PCa, cancer grade, and molecular effects. A multi-database search was used to identify original clinical and preclinical research articles examining RAGE expression in PCa. After screening and review, nine clinical and six preclinical articles were included. The associations of RAGE differentiating benign prostate hyperplasia (BPH) or normal prostate from PCa and between tumor grades were estimated using odds ratios (ORs) and associated 95% confidence intervals (CI). Pooled estimates were calculated using random-effect models due to study heterogeneity. The clinical meta-analysis found that RAGE expression was highly likely to be increased in PCa when compared to BPH or normal prostate (OR: 11.3; 95% CI: 4.4–29.1) and that RAGE was overexpressed in high-grade PCa when compared to low-grade PCa (OR: 2.5; 95% CI: 1.8–3.4). In addition, meta-analysis estimates of preclinical studies performed by albatross plot generation found robustly positive associations among RAGE expression/activation and PCa growth and metastatic potential. This review demonstrates that RAGE expression is strongly tied to PCa progression and can serve as an effective diagnostic target to differentiate between healthy prostate, low-grade PCa, and high-grade PCa, with potential theragnostic applications.
Cytowania
-
4
CrossRef
-
0
Web of Science
-
3
Scopus
Autorzy (6)
-
Catherine C. Applegate
-
Michael B. Nelappana
-
Elaine A. Nielsen
-
Iwona T. Dobrucki
-
Lawrence W. Dobrucki
Cytuj jako
Pełna treść
- Wersja publikacji
- Accepted albo Published Version
- DOI:
- Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.3390/cancers15194889
- Licencja
-
otwiera się w nowej karcie
Słowa kluczowe
Informacje szczegółowe
- Kategoria:
- Publikacja w czasopiśmie
- Typ:
- artykuły w czasopismach
- Opublikowano w:
-
Cancers
nr 15,
ISSN: 2072-6694 - Język:
- polski
- Rok wydania:
- 2023
- Opis bibliograficzny:
- Applegate C. C., Nelappana M. B., Nielsen E. A., Kalinowski L., Dobrucki I. T., Dobrucki L. W.: RAGE as a Novel Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis// Cancers -Vol. 15,iss. 19 (2023), s.4889-
- DOI:
- Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.3390/cancers15194889
- Źródła finansowania:
-
- This work was supported by the Beckman Foundation. M.B.N. was supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Award Number T32EB019944.
- Weryfikacja:
- Politechnika Gdańska
wyświetlono 47 razy
Publikacje, które mogą cię zainteresować
Receptor for advanced glycation end‐products: Biological significance and imaging applications
- I. T. Dobrucki,
- A. Miskalis,
- M. B. Nelappana
- + 5 autorów
Molecularly targeted nanoparticles: an emerging tool for evaluation of expression of the receptor for advanced glycation end products in a murine model of peripheral artery disease
- M. Woźniak,
- C. J. Konopka,
- A. Płoska
- + 7 autorów
Folate/homocysteine metabolism and lung cancer risk among smokers
- A. Stanisławska-Sachadyn,
- J. Borzyszkowska,
- M. Krzemiński
- + 5 autorów